INTRODUCTION: Research has been limited in circadian activity rhythms and their relationship with health status in early-stage breast cancer survivors. Maintaining strong circadian parameters may reduce symptoms and improve physical functioning and disease-free survival. METHODS: This is a descriptive, correlational, secondary analysis of data from a randomized controlled trial collected 1 year after the first chemotherapy treatment; n = 156 cases with 7 days of wrist actigraph data of six circadian activity rhythm parameters; measures of function, fatigue, sleep, and anxiety/depression; and demographic/medical data including body mass index (BMI). RESULTS: In the total sample and three BMI categories, acrophase was the only circadian parameter that reached means established in healthy adults. In the total sample, phase-delayed acrophase was associated with higher depression (r = 0.180, p = 0.025) and lower morning energy (r = -0.194, p = 0.016) and trended for higher fatigue (r = 0.153, p = 0.057). Lower morning energy was also associated with a lower circadian quotient (r = 0.158, p = 0.05). As BMI increased, weaker circadian parameters were recorded consistently. When compared with women in normal BMI categories, obese women's amplitude and 24-h autocorrelation coefficient were significantly weaker (p = 0.011-0.015). In obese women, phase-delayed acrophase was correlated with higher fatigue and anxiety and with lower morning energy and physical functioning. DISCUSSION/ CONCLUSIONS:Amplitude and 24-h autocorrelation parameters were significantly weaker, and phase-delayed acrophase was linked to several more intense symptoms and lower physical functioning in obese women. IMPLICATIONS FOR CANCER SURVIVORS: Clinicians need to target high-risk women with phase-delayed rhythms, higher symptoms, and lower physical functioning for intervention.
RCT Entities:
INTRODUCTION: Research has been limited in circadian activity rhythms and their relationship with health status in early-stage breast cancer survivors. Maintaining strong circadian parameters may reduce symptoms and improve physical functioning and disease-free survival. METHODS: This is a descriptive, correlational, secondary analysis of data from a randomized controlled trial collected 1 year after the first chemotherapy treatment; n = 156 cases with 7 days of wrist actigraph data of six circadian activity rhythm parameters; measures of function, fatigue, sleep, and anxiety/depression; and demographic/medical data including body mass index (BMI). RESULTS: In the total sample and three BMI categories, acrophase was the only circadian parameter that reached means established in healthy adults. In the total sample, phase-delayed acrophase was associated with higher depression (r = 0.180, p = 0.025) and lower morning energy (r = -0.194, p = 0.016) and trended for higher fatigue (r = 0.153, p = 0.057). Lower morning energy was also associated with a lower circadian quotient (r = 0.158, p = 0.05). As BMI increased, weaker circadian parameters were recorded consistently. When compared with women in normal BMI categories, obesewomen's amplitude and 24-h autocorrelation coefficient were significantly weaker (p = 0.011-0.015). In obesewomen, phase-delayed acrophase was correlated with higher fatigue and anxiety and with lower morning energy and physical functioning. DISCUSSION/ CONCLUSIONS: Amplitude and 24-h autocorrelation parameters were significantly weaker, and phase-delayed acrophase was linked to several more intense symptoms and lower physical functioning in obesewomen. IMPLICATIONS FOR CANCER SURVIVORS: Clinicians need to target high-risk women with phase-delayed rhythms, higher symptoms, and lower physical functioning for intervention.
Authors: Kathleen Meeske; Ashley Wilder Smith; Catherine M Alfano; Bonnie A McGregor; Anne McTiernan; Kathy B Baumgartner; Kathleen E Malone; Bryce B Reeve; Rachel Ballard-Barbash; Leslie Bernstein Journal: Qual Life Res Date: 2007-04-25 Impact factor: 4.147
Authors: Michael Littner; Clete A Kushida; W McDowell Anderson; Dennis Bailey; Richard B Berry; David G Davila; Max Hirshkowitz; Sheldon Kapen; Milton Kramer; Daniel Loube; Merrill Wise; Stephen F Johnson Journal: Sleep Date: 2003-05-01 Impact factor: 5.849
Authors: Bette J Caan; Marilyn L Kwan; Georgina Hartzell; Adrienne Castillo; Martha L Slattery; Barbara Sternfeld; Erin Weltzien Journal: Cancer Causes Control Date: 2008-08-28 Impact factor: 2.506
Authors: Kristin Valborg Reinertsen; Milada Cvancarova; Jon H Loge; Hege Edvardsen; Erik Wist; Sophie D Fosså Journal: J Cancer Surviv Date: 2010-09-23 Impact factor: 4.442
Authors: James F Grutsch; Patricia A Wood; Jovelyn Du-Quiton; Justin L Reynolds; Christopher G Lis; Robert D Levin; Mary Ann Daehler; Digant Gupta; Dinah Faith T Quiton; William Jm Hrushesky Journal: J Circadian Rhythms Date: 2011-05-18
Authors: Meredith E Rumble; Stephen L Rose; Kaitlin Hanley White; A Holliston Moore; Philip Gehrman; Ruth M Benca; Erin S Costanzo Journal: Gynecol Oncol Date: 2015-04-21 Impact factor: 5.482
Authors: Fay Wright; Gail D'Eramo Melkus; Marilyn Hammer; Brian L Schmidt; M Tish Knobf; Steven M Paul; Frances Cartwright; Judy Mastick; Bruce A Cooper; Lee-May Chen; Michelle Melisko; Jon D Levine; Kord Kober; Bradley E Aouizerat; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2015-03-28 Impact factor: 3.612
Authors: Kyle A Sullivan; Savannah R Bever; Daniel B McKim; Jonathan P Godbout; John F Sheridan; Karl Obrietan; Leah M Pyter Journal: Brain Behav Immun Date: 2019-05-17 Impact factor: 7.217
Authors: Andrew Kirvin-Quamme; Meredith E Rumble; Lisa Cadmus-Bertram; Mark B Juckett; Paul J Rathouz; Gwynneth Schell; Natalie S Callander; Peiman Hematti; Erin S Costanzo Journal: Contemp Clin Trials Commun Date: 2022-05-28
Authors: Sonia Ancoli-Israel; Lianqi Liu; Michelle Rissling; Loki Natarajan; Ariel B Neikrug; Barton W Palmer; Paul J Mills; Barbara A Parker; Georgia Robins Sadler; Jeanne Maglione Journal: Support Care Cancer Date: 2014-04-15 Impact factor: 3.603
Authors: Julie L Otte; Janet S Carpenter; Shalini Manchanda; Kevin L Rand; Todd C Skaar; Michael Weaver; Yelena Chernyak; Xin Zhong; Christele Igega; Carol Landis Journal: Cancer Med Date: 2014-11-30 Impact factor: 4.452